Study of TRC102 in Combination With Pemetrexed in Cancer Patients

Completed · Phase 1

Conditions studied: Neoplasm

In brief

This study is being performed to evaluate the safety and tolerability of TRC102 in combination with Alimta. In addition to safety, this study will also evaluate pharmacokinetics and tumor response.

Key facts

Study ID

NCT00692159

Run by

Tracon Pharmaceuticals Inc.

People needed

28

Starts

2008-06-01

Expected to finish

2010-09-01

Last updated by the study team

2010-09-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient has given informed consent
• The patient is willing and able to abide by the protocol
• The patient has cancer and curative therapy is unavailable or standard therapy has failed
• The patient is at least 18 years of age
• The patient has adequate ability to perform activities of daily living
• The patient has recovered from significant toxicities of previous therapy
• The patient has adequate organ function as assessed by laboratory testing

You may not qualify if…

• The patient has had prior treatment with high-dose chemotherapy requiring stem cell rescue
• The patient is currently on treatment on another therapeutic clinical trial or has received an investigational drug within 4 weeks prior to first dose on this study
• The patient has had prior surgery, radiation or systemic therapy within 4 weeks of starting the study
• The patient has a history of CNS cancer
• The patient has an unstable medical condition including (not limited to) cardiac disease, HIV/AIDS, history of stroke, hepatitis or significant paricardial, pleural or peritoneal effusion
• The patient is pregnant or breastfeeding

Where it is running

• Study site — Scottsdale, Arizona, United States
• Study site — Santa Monica, California, United States
• Study site — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.